RAPID Pathway: Ensuring Timely Medicare Coverage for Breakthrough Devices
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. This initiative focuses on specific FDA-designated Breakthrough Devices, aiming to offer predictable national Medicare coverage concurrently with or shortly after a device's market entry.
Typically, CMS initiates the national coverage determination (NCD) process only after a device receives FDA authorization, a timeline that can stretch nine to 12 months. During this period, devices might remain without guaranteed coverage, posing significant financial risks to beneficiaries and healthcare systems. The new RAPID pathway seeks to address this by ensuring timely Medicare coverage, building on previous efforts such as the Parallel Review pathway.
Under RAPID, CMS will collaborate with the FDA during the regulatory review process. This aims to guide medical device companies on evidence requirements for both FDA approval and CMS coverage. While RAPID doesn't alter the FDA's approval standards, CMS's early involvement may influence aspects such as study design and evidentiary standards, potentially impacting a device's market readiness.
Eligibility and Strategic Considerations
The RAPID pathway is available for Class III devices and certain Class II devices within the FDA's Total Life Cycle Advisory Program (TAP). These devices must address unmet medical needs within the Medicare population. Eligibility requires participation in an Investigational Device Exemption (IDE) study involving Medicare beneficiaries, with health outcomes aligned with both FDA and CMS standards.
Medical technology companies considering RAPID face strategic decisions. While CMS might demand more robust evidence than the FDA, requiring larger and costlier trials, the advantage is swift national Medicare coverage upon successful approval. This pathway may enhance opportunities for quicker commercial payer coverage and improve positioning in clinical guidelines.
RAPID may permit CMS flexibility with pre-market evidence requirements, possibly allowing for post-market evidence generation. A proposed NCD would be published the same day as FDA authorization, followed by a 30-day public comment period, potentially expediting the coverage process to as few as two months.
An NCD ensures uniform Medicare coverage for fee-for-service beneficiaries, compelling all Medicare Advantage plans to align with this, though prior authorization could still be required. Consequently, medical device companies can confidently assure Medicare beneficiaries and healthcare providers about coverage for new technologies. Details and clarifications are expected in an upcoming Federal Register notice, open for public commentary for 60 days.